|Publication number||US5085629 A|
|Application number||US 07/414,651|
|Publication date||Feb 4, 1992|
|Filing date||Sep 27, 1989|
|Priority date||Oct 6, 1988|
|Also published as||CA2025626A1, EP0420541A2, EP0420541A3|
|Publication number||07414651, 414651, US 5085629 A, US 5085629A, US-A-5085629, US5085629 A, US5085629A|
|Inventors||Jay Goldberg, Richard Sinclair|
|Original Assignee||Medical Engineering Corporation|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (16), Non-Patent Citations (8), Referenced by (281), Classifications (21), Legal Events (12) |
|External Links: USPTO, USPTO Assignment, Espacenet|
US 5085629 A
A biodegradable, biocompatible, resorbable infusion stent comprising a terpolymer of:
(b) glycolide, and
This invention includes a method for treating ureteral obstructions or impairments by utilizing a biodegradable, biocompatible, resorbable infusion stent, and a method for controlling the speed of resorption of the stent.
What is claimed is:
1. A biodegradable, biocompatible, resorbable, ureteral stent having retaining means to prevent migration from a predetermined position in the ureter, said stent comprising a terpolymer of:
(a) L(-) lactide
(b) glycolide, and
2. The ureteral stent of claim 1, wherein the epsilon-caprolactone varies from about 15 to 25 weight %.
3. The ureteral stent of claim 1, wherein the L(-)lactide varies from about 45 to 85 weight %.
4. The ureteral stent of claim 1, wherein the glycolide varies from about 5 to 50 weight %.
5. The ureteral stent of claim 1, also including about 5 to 30 weight % of a radiopaque material.
6. The ureteral stent of claim 5, wherein said radiopaque material is finely divided barium sulfate.
7. The ureteral stent of claim 1, wherein the modulus varies from about 6000 to 7000 psi.
8. The ureteral stent of claim 1, bendable into a pliable curl set at each end.
9. The ureteral stent of claim 1, sterilizable and capable of compounding with radiopaque materials.
10. The ureteral stent of claim 1, in transparent form.
11. The ureteral stent of claim 1, wherein the terpolymer has a weight average molecular weight varying from about 20,000 to 1,000,000.
12. The ureteral stent of claim 1, wherein the terpolymer has a melt process decomposition temperature greater than or equal to about 230° C.
13. The ureteral stent of claim 1, wherein the terpolymer has a tube extrusion processing temperature that varies from about 135° to 150° C.
14. The ureteral stent of claim 11, wherein, the terpolymer has a weight average molecular weight of about 50,000 to 400,000.
15. The ureteral stent of claim 1, having:
(i) a tensile strength of at least about 500 psi,
(ii) an elongation greater than about 10%, and
(iii) Shore A hardness of about 50 to 100.
16. A method for treating ureteral obstruction or impairment in a mammalian host by inserting in the ureter in a predetermined location, a biodegradable, biocompatible resorbable non-anastomosis polymeris stent extending between the kidney and the bladder, said stent having end portions with pliable retaining means to prevent migration before biodegradation, without the need for suturing, from the predetermined location in the ureter.
17. The method of claim 16, wherein said stent has the following properties:
(i) a tensile strength of at least about 500 psi,
(ii) an elongation greater than about 10%, and
(iii) Shore A hardness of about 50 to 100.
18. The method of claim 16, wherein the stent has the following properties:
(a) tensile strength greater than 1000 psi,
(b) elongation greater than 100%, and
(c) Shore A hardness of about 75 to 95.
19. The method of claim 16, wherein said stent comprises a polymeric material having a weight average molecular weight varying from about 50,000 to 400,000.
20. The method of claim 16, wherein the stent comprises at least one polymer selected from the group consisting of L(-)lactide, glycolide, epsilon-caprolactone, D(-)lactide, meso-lactide, D,L-lactide, and delta-valero-lactone.
21. The method of claim 29, wherein the stent comprises of terpolymer of:
(b) glycolide, and
22. The method of claim 21, wherein the L(-)lactide varies from about 45 to 85 weight %.
23. The method of claim 21, wherein the glycolide varies from about 5 to 50 weight %.
24. The method of claim 21, wherein the epsilon-caprolactone varies from about 15 to 25 weight %.
25. A method for controlling the time of biodegradation in the ureter of a polymeric, biodegradable, biocompatible, resorbable non-anastomosis ureteral stent by
(a) inserting a stent in the ureter in a predetermined location between the kidney and the bladder to relieve ureteral obstruction;
(b) providing end portions of the stent with pliable retaining means to prevent migration of the stent before biodegradation, without the need for suturing; and
(c) controlling the rate of biodegradation of said polymeric stent from a few weeks to a few months, by varying the molecular weight of the polymer composition comprising the stent, from a weight average molecular weight of about 20,000 to about 1,000,000.
26. The method of claim 25, wherein the stent comprises a terpolymer of:
(b) glycolide, and
27. The method of claim 25, wherein the weight average molecular weight of said polymeric stent varies from about 50,000 to about 400,000.
28. The method of claim 25, wherein the stent comprises at least one polymer selected from the group consisting of L(-)lactide, glycolide, epsilon-caprolactone, D(-)lactide, meso-lactide, D,L-lactide, and delta-valero-lactone.
29. The method of claim 25, wherein the average molecular weight varies from about 50,000 to about 400,000.
30. The method of claim 25, wherein said stent has the following properties:
(i) a tensile strength of at least about 500 psi,
(ii) an elongation greater than about 10%, and
(iii) Shore A hardness of about 50 to 100.
31. A method for relieving ureteral obstruction in a mammalian host, comprising:
(a) forming a tubular polymeric, biodegradable, biocompatible resorbable non-anastomosis ureteral stent having end portions with pliable retaining means to prevent migration before biodegradation, without the need for suturing, from a predetermined position in the ureter, and wherein said stent substantially extends from the kidney to the bladder;
(b) controlling the rate of biodegradation of said polymeric stent by varying the molecular weight of the polymer composition comprising the stent, from a weight average molecular weight of about 50,000 to about 1,000,000, and
(c) inserting said positioning said ureteral stent in the ureter in a predetermined location between the kidney and the bladder.
32. The method of claim 31, wherein said stent has the following properties:
(i) a tensile strength of at least about 500 psi,
(ii) an elongation greater than about 10%, and
(iii) Shore A hardness of about 50 to 100.
This is a continuation-in-part of application Ser. No. 254,547 filed on Oct. 6, 1988, and now abandoned.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the preparation of ureteral stents from biodegradable polymers of lactic acid.
2. Description of the Prior Art
Ureteral stents are often used to maintain fluid drainage from the renal pelvis to the bladder when the ureter is obstructed or otherwise impaired, and also for providing support to a collapsed or restricted ureter.
Very often, ureteral stents are positioned in a patient on a temporary basis to provide drainage from the kidney to the bladder following surgery. The stent is generally coiled or looped at opposite ends to prevent upward or downward migration from a predetermined position in the ureter caused by peristaltic action or other body motion that would impose forces on the stent to move it from its predetermined position.
Certain ureteral stents have the capability of infusing fluids into the kidney and are commonly referred to as "infusion stents".
In many situations where the ureteral stent is installed for short term usage, an additional surgical procedure must be employed to remove the stent after its purpose has been fulfilled.
A ureteral stent that is made of a biodegradable and biocompatible material would assure its safe and innocuous disappearance without the need for a second surgical procedure for its removal after it has completed its function.
Canadian Patent No. 808,731 to Fouty discloses the preparation of high molecular weight polylactides with an anionic coordination catalyst containing a divalent metal of Group II of the Periodic Table, to produce a polymer containing the divalent metal as part of the polylactide. Either optical isomer of lactide may be used, and the lactide can be copolymerized with other cyclic esters having from 6 to 8 carbon atoms in the ring, such as glycolide or tetramethyl glycolide.
U.S. Pat. No. 4,045,418 to Sinclair discloses thermally stable copolymers of optically inactive lactide and epsilon caprolactone with a tin ester of carboxylic acid serving as a catalyst to produce throwaway thermoplastic objects that are environmentally attractive because they slowly degrade to harmless substances. Cyclic esters such as glycolide, lactide and the lactones are also disclosed as being used to produce thermoplastics. U.S. Pat. No. 4,057,537 also to Sinclair discloses the copolymerization of glycolide with lactide and various lactones to form copolymers which are reported as useful in making absorbable sutures. Sinclair's primary objective is to produce a non-gummy, high impact, non-brittle, thermally stable copolymer of an optically active lactide and epsilon-caprolactone which can be fabricated into various thermoplastic objects that are disposable and environmentally attractive since they degrade into harmless substances.
U.S. Pat. No. 3,844,987 to Clendinning et al, discloses shaped containers fabricated from biodegradable thermoplastic oxyalkanoyl polymers, such as epsilon-caprolactone polymers, and naturally occurring biodegradable substances to serve as containers in which to germinate and grow seed or seedlings.
U.S. Pat. No. 3,636,956 to Schneider discloses copolymers of L(-)lactide with up to 35% glycolide for use in surgical applications such as sutures and ligatures. U.S. Pat. No. 3,739,773 to Schmitt et al, discloses polyglycolic acid or polyhydroxyacetic ester can be surgically used for a solid prosthesis or a protective gauze and is absorbable by living mammalian tissue.
U.S. Pat. No. 3,736,646 to Schmitt discloses a copolymer containing 15 to 85 mole % of both glycolic and lactic acid can be formed into biodegradable surgical structures such as tubes or sheets or spun as filaments to prepare sutures.
U.S. Pat. No. 4,300,565 to Rosensaft et al, discloses a method for producing sterile surgical articles from a synthetic absorbable copolymer formed by copolymerizing glycolide monomer with a cyclic ester monomer other than a glycolide, such as a lactone, oxalate or carbonate.
U.S. Pat. No. 3,531,561 to Trehu discloses the use of high molecular weight polylactides extruded to form a surgical suture.
U.S. Pat. No. 4,539,981 to Tunc discloses an absorbable bone fixation device made from a polymer of L(-)lactide with an inherent viscosity above 4.5.
U.S. Pat. No. 4,181,983 to Kulkarni discloses an assimilable, porous, hydrophilic prosthesis composed of a polymer of hydroxycarboxylic acid, with the preferred polymer being a lactic acid.
U.S. Pat. No. 4,137,921 to Okuzumi discloses the formation of highly crystalline, fiber-forming addition copolymers of lactide and glycolide having from 50 to 75% glycolide. The lactide-glycolide addition copolymers are highly crystalline and useful in forming fibers for surgical sutures.
U.S. Pat. No. 3,839,927 to Wasserman et al, discloses the formation of a high molecular weight 1-lactide/glycolide copolymer using a stannous octoate catalyst. The copolymer may be extruded to form filaments useable as absorbable sutures.
European Patent Application No. 0204931 to Pertti et al, discloses a synthetic polymeric surgical osteosynthesis material absorbable by the body composed of such polymers as a polylactide.
Other patents of interest relating to the preparation of polylactides include U.S. Pat. Nos. 2,703,316 to Schneider; 2,890,208 to Young et al; 2,362,511 to Teeters; 3,169,945 to Hostettler et al; 3,284,417 to Hostettler et al; 2,758,987 to Salzburg et al and Canadian Patent 779,291 to Kleine.
SUMMARY OF THE INVENTION
The present invention is based upon the discovery of a biodegradable, biocompatible, resorbable infusion stent comprising a terpolymer of:
(b) glycolide, and
This invention is also based upon a method for treating ureteral obstruction or impairment by utilizing a biodegradable, biocompatible, resorbable infusion stent, and a method for controlling the rate of biodegradation of the stent.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
In accordance with the present invention, it has been found that a biocompatible, biodegradable, resorbable infusion stent can be made from a terpolymer of:
(b) glycolide, and
The inventive infusion stent has the following properties:
(i) a minimum tensile strength of at least about 500 psi, preferably at least about 650 psi,
(ii) an elongation greater than about 10%, preferably greater than about 100%,
(iii) Shore A hardness of about 50 to 100, preferably about 75 to 95
In addition, the biodegradable stent is pliable, and can be fabricated or extruded into tubing with an inside diameter that can vary from about 0.050 to about 0.075 inches, and an outside diameter than can vary from about 0.075 to about 0.120 inches.
The inventive stent can be made transparent and is biocompatible. Because it is also biodegradable, the stent disintegrates in mammalian body tissue, within a few weeks to a few months, without interfering with urinary function.
The inventive stent can be fabricated with a pliable curl set at each end by heat setting techniques, can be sterilized, and is capable of being compounded with radiopaque materials such as barium sulfate. The stent should have a minimum curl strength of at least about 4 grams, and a minimum break strength of about 1.7 pounds. The stent can also be imprinted with biocompatible inks.
It has been found that the controlling factor in the stiffness of the terpolymer composition used in making the stent is the amount of epsilon-caprolactone which can vary between about 15 and about 25% by weight of the terpolymer composition. At about 15 weight % or less, the terpolymer composition becomes too stiff, and at about 25 weight % or higher, the composition becomes too pliable and weak to construct the stent. A 20 weight % caprolactone terpolymer is most preferred for its pliability characteristics.
The amounts of L(-)lactide can vary from about 45 to 85 weight %, preferably about 55 to 75 weight % and most preferably about 60 to 70 weight % of the terpolymer composition.
The amounts of glycolide can vary from about 5 to 50 weight %, and preferably about 10 to 30 weight % of the terpolymer composition. The blending of those components produces a pliable, transparent, thermoplastic elastomer that is biodegradable and biocompatible.
The mechanism of biodegradation of the inventive stent is essentially one of hydrolysis; that is, the destruction, decomposition, or alteration of the chemical composition of the stent by water to the point where the stent disintegrates and is harmlessly excreted from the body in the urine. At the same time, certain portions of the stent which are in contact with the body tissues are resorbed into the tissues. For purposes of this invention, the terms "biodegradation, biodegradable" and the like are intended to also include resorption of the stent in the body tissues.
It has been found that when the glass transition temperature (Tg) of the biodegradable composition which comprises the stent is less than about 37° C., biodegradation proceeds at a more rapid rate than when the Tg is about 37° C. or greater.
Tg is defined as a second order transition temperature which results in a discontinuity of properties of a polymer composition. At the Tg, the polymer will change from a stiff to a more flexible state, and its density and molecular free volume will increase.
Thus, when the Tg is less than about 37° C., the polymeric composition comprising the stent becomes more susceptible to penetration by body fluids and the time of biodegradation proceeds more rapidly.
The process of biodegradation of the stent begins from the time the stent is initially implanted between the kidney and bladder. However, the rate at which biodegradation occurs can be controlled to assure that the stent will function for the desired period of time which can range from a matter of weeks to two or three months or even longer as the requirement demands, based upon the individual condition and needs of the patient. Most preferably, the useful life of the stent, which is the time during which the stent continues to function and operate, will vary from about 3 to 7 weeks.
Factors which are influential in controlling the rate of biodegradation, which directly relate to the useful life of the stent, include the molecular weight of the stent composition and the amorphous nature of the stent composition. A reduction in molecular weight is indicative of biodegradation. The more amorphous the stent terpolymer composition is, the faster it will biodegrade.
The inventive terpolymer should have a weight average molecular weight of about 20,000 to 1,000,000. preferably about 50,000 to 400,000, and is generally monomodal with respect to molecular weight distribution.
The inventive terpolymer can be melt processed without decomposing at temperatures of 230° C. and below. The terpolymer is thixotropic and most readily processable at temperatures from about 135° to 150° C.
Important factors involved in tube fabrication include the shear rate in the extruder and temperature. The preferred processing temperature for tube extrusion varies from about 135° to 150° C. Processing at all conditions reduces the average molecular weight and affects all molecules similarly. The shear rate in the extruder should be maintained as low as possible to reduce the amount of melt fracture and molecular weight degradation. Thus, it is important in the processing to preferably maintain the shear rate in the extruder to about 500 to 1000 sec-1 to maintain physical properties as close to the original material as possible.
It is also desirable to incorporate or blend radiopaque materials such as barium sulfate with the terpolymer in amounts varying from about 5 to 30 weight %, preferably about 10 to 20 weight % of the terpolymer composition. The barium sulfate is finely divided to a particle size which makes it homogeneous and compatible with the terpolymer, without affecting its light transmission properties. A suitable particle size is where 99% of the particles pass through 325 mesh or a 45 micron opening.
The present invention also provides a method for treating and remedying a ureteral obstruction or impairment with a ureteral stent without the necessity for an additional surgical procedure to remove the stent after it has performed its function and is no longer needed. The use of the inventive biodegradable, biocompatible and resorbable ureteral stent assures its safe and innocuous disappearance by biodegradation at a controlled and predictable rate after the stent has fulfilled its function. The controlled predictable rate of biodegradation is based upon such factors as molecular weight and extent of the amorphous nature of the terpolymer composition. Thus, the only surgical procedure necessary is the initial insertion and positioning of the ureteral stent between the kidney and the bladder. Removal is accomplished by biodegradation of the stent.
The following examples illustrate specific embodiments of the present invention. In the examples and throughout the invention all parts and percentages are by weight, unless otherwise indicated.
EXAMPLE 1 Starting Materials
High-purity L(-)lactide is available from commercial sources, under the trademark Crystallization 3™ from Purac Inc., affiliated with CCA biochem bv. of The Netherlands, and under the trademark L-Lactide S™ from Henley and Co., a subsidiary of Boehringer Ingelheim of Germany. Glycolide is available under the trademark Glycolide S™ from Henley and Co.
Epsilon-caprolactone having a purity above 99% is purchased from commerical sources, such as Aldrich Company Catalog No. 16736-3, and is further purified by vacuum distillation through a Claisen head at 10 to 20 torr, to a water white cut at 90° to 115° C. with a boiling point range of about ±2° C. The distillation i discontinued when the pot supply is low and with the temperature rising at constant pressure. The distillate is stored under a moisture free nitrogen or argon atmosphere.
The catalyst, stannous octoate, is available from M&T Chemicals, Rahway, NJ as an anhydrous solution. About 10 milliliters of dried CP (certified pure) or AP (analyzed pure) grade toluene and 20 milliliters of stannous octoate was pipetted into a 200 to 300 ml flask, equipped with either an argon or nitrogen purge and a Dean-Stark type trap that was capped with a Drierite drying tube. The empty apparatus was previously flame-dried and cooled under nitrogen. The toluene solution was brought to reflux under a nitrogen trickle and 10 milliliters was distilled, to insure that the last few milliliters were clear.
EXAMPLE 2 Preparation of Terpolymer
65 parts of L(-)lactide (L-lactide S™, Henley and Co.), 15 parts of glycolide (Glycolide S™, Henley and Co.), and 20 parts of purified epsilon-caprolactone, (Aldrich Catalog No. 16736-3; Chemical Abstracts No. 502-44-3) were placed in an ampoule followed by the addition of 0.10 milliliters of a 20% stannous octoate solution in toluene. The amount of stannous octoate catalyst solution was 0.10 milliliters per 100 grams of total lactide, glycolide and epsilon-caprolactone. The ampoule was evacuated with a vacuum pump for at least 10 minutes and sealed at its constriction. The contents were melted by placing the ampoule in a 140° to 160° C. oil bath, while mixing the melt by swirling until the melt became viscous. Heating continued for about 16 to 72 hours at 140° to 160° C. The ampoule was removed from the oil bath, and cooled to room temperature. The terpolymer product was removed from the ampoule and stored in a desiccator. The terpolymer was transparent and nearly colorless. Its weight average molecular weight, as measured by gel permeation chromatography (GPC) was greater than 100,000.
The preparatory procedure was again repeated using different amounts of the components as tabulated in Table 1.
TABLE 1______________________________________TERPOLYMER COMPOSITION, Weight %Sample No. L(-)lactide Glycolide Epsilon-caprolactone______________________________________1 60 15 252 37.5 37.5 253 15 60 254 65 15 205 85 0 15______________________________________
Each of the samples was then tested for various physical properties tabulated in Table 2.
TABLE 2______________________________________SUMMARY OF PHYSICAL PROPERTIES Elong-Sample Tensile.sup.(a) ation.sup.(a)No. Strength, psi percent Modulus.sup.(b) Shore, A______________________________________1 1627 596 506 512 439 600 377 523 1383 35 8791 96.sup.(c)3 1693.sup.(d) 40 9908 964 1511 954 4035 94 4.sup.(e) 1654 564 382 605 4558 275.sup.(f) 110,368 (Shore D,75)______________________________________ Footnotes for Table 2 .sup.(a) Average of 5 specimens, ASTM D638, 70 mil thickness, crosshead speed 20 in./min. .sup.(b) Plastic or initial tangent modulus. .sup.(c) Shore D: 54 .sup.(d) Crosshead speed 2 in./min. .sup.(e) Tested at 37° C. .sup.(f) To failure, but 5% to yield.
EXAMPLE 3 Compression Molding of Terpolymers
Sheets of approximately 75 mil were compression molded in accordance with the following procedure:
60 grams of each terpolymer sample prepared in accordance with Example 2 were placed between silicone release paper in a polished, stainless steel hinged mold preheated in a press to the temperatures shown in Table 3.
TABLE 3______________________________________Sample No. Molding Temp. °F. Platen Pressure (psi)______________________________________1 250 5,000 for 2 min. 10,000 for 3 min.2 250 same as sample No. 13 205 "4 266 "5 330 20,000 for 1 min.______________________________________
Contact pressure was maintained on the mold for approximately 2 to 5 minutes until the polymer flowed into the mold cavity. Platen pressure of 5,000 to 2,000 pounds was applied for 1 to 3 minutes as shown in Table 2. The mold was then put into a cooling press under the same platen pressure and held until cooled to room temperature. The sheet of polymer for each sample was removed from the mold and release paper and specimens were cut from the sheet for tensile tests, with the results tabulated in Table 4.
TABLE 4______________________________________ELASTOMER MODULI AT 100 AND 200% ELONGATION.sup.(a)Sample No. 100% Modulus (psi) 200% Modulus (psi)______________________________________1 155 2272 162 1883 446 4894 214 2945 2130 3160______________________________________ .sup.(a) Elastomer modulus is psi load at 100% and 200% elongation.
EXAMPLE 4 Characterization of Molecular Weight and Thermal Properties
A molecular weight analysis and thermal characterization of several samples of L(-)lactide/glycolide/epsilon-caprolactone terpolymer with component ratios of 65/15/20 in parts by weight was conducted.
Molecular weight distribution and averages were determined using a Waters Model 150 C ALC/GPC SEC with a Model 820 data station and Maxima software. Operating parameters used to determine the molecular weight are listed in Table 5. Table 6 shows molecular weights calculated for the samples.
Table 5 Operating Parameters for Molecular Weight Analysis
Columns: 106 -105 -104 -103 Å μ Styragel
Solvent: Burdick & Jackson DIG Tetrahydrofuran
Flow Rate: 1 ml/min
Injection Volume: 100 μl
Temperature: 23° C. (RT)
Nominal Concentration: 2 mg/ml
Detector: Refractive Index
Standards: Narrow distribution polystyrene
TABLE 6______________________________________Molecular Weights of Terpolymer SamplesBefore and After Extrusion Into TubingDescription Mn, 1000's Mw, 1000's Mz, 1000's Mw /Mn______________________________________Beforeprocessing -Sample 1 106 197 342 1.88Sample 2 145 310 591 2.14Beginning ofextrusion -Sample 1 86 173 300 2.01Sample 2 104 228 526 2.18Middle ofextrusion -Sample 1 90 177 303 1.97Sample 2 103 204 364 1.98End ofextrusion -Sample 1 85 171 302 2.00Sample 2 97 200 375 2.07______________________________________
The terpolymers were monomodal with respect to molecular weight distribution. Although the polymers showed a decrease in molecular weight upon melt fabrication, the decrease was not significant in terms of loss of physical properties.
Thermal gravimetric analysis (TGA) and differential scanning calorimetry (DSC) were performed on the terpolymers. Inhomogeneity, as evidenced by melting points of monomers, or weight loss on programmed heating, as well as melting points of homopolymers was not detectable. The terpolymers were pure and homogeneous, and contained at most ppm quantities of unreacted monomer. The terpolymer could be melt processed without decomposition at 230° C. and below. The material was thixotropic (shear thinning) and processible at approximately 138°-148° C.
EXAMPLE 5 Formation of Small Diameter Tubes
A Brabender single screw 3/4 inch diameter extruder with 30 L/D was used with a die to manufacture small tube diameters. The take up device, a Univex Take-off from C. W. Brabender, was placed after a 6 foot water bath. The terpolymer composition of Example 4 was used. The initial processing temperatures for tube extrusion were 138° to 148° C. The shear rate in the extruder was maintained in the range of 500 to 1000 sec.-1 to minimize the amount of melt fracture and molecular weight degradation. The molecular weights were determined using Maxima 820 GPC analysis, with results shown in Table 7 as follows:
TABLE 7______________________________________Molecular WeightsTemperature Mn Mw°C. Number Average Weight Average______________________________________Unprocessed 126412 295015control138 103062 203780148 90005 176878______________________________________
The extrusion temperature profile from the feed zone to the die was as follows:
______________________________________Zone Temperature ° C.______________________________________1 (feed) 1382 1433 1464 (die) 148______________________________________
The terpolymer was extruded to produce a tube with an inside diameter of 0.072 inch and outside diameter of 0.111 inch. This test demonstrated that the biodegradable terpolymer can be extruded into small tubes with the desired diameter using the processing conditions described. Important factors involved in tube fabrication were shear history and temperature. Processing at all conditions reduced the molecular weight averages and affected all molecules similarly. Thus, it was important in the processing to maintain the shear rate in the extruder at a minimum to maintain original material properties. The processing temperature also affected the final molecular weight. The higher the processing temperature, the lower the calculated molecular weight averages. Therefore, it is preferable to operate the extruder at the low end of the processing temperature range of the terpolymer (138° to 148° C.).
EXAMPLE 6 Blending of Terpolymer with Barium Sulfate Followed by Extrusion
A terpolymer having the same composition as that in Example 5 was melt blended with 12 percent by weight of small, micron size particulate BaSO4 on a two roll mill at 280° F. The BaSO4 was homogeneous and compatible with the terpolymer. The terpolymer resin filled with the BaSO4 was then ground with dry ice and placed in an oven at 100° F. for 1 hour to remove excess moisture. To complete the drying, the material was placed in a vacuum oven at room temperature overnight.
The filled copolymer was extruded into a tube using a 3/4 inch Brabender extruder with 30:1 length to diameter ratio. Additional die parts were used for the small diameter requirements. A 6-foot water bath and a take up device followed the extruder to cool and control the size of the tubing. Air was also fed through the middle of the die to maintain the tube shape until the material cooled and established its own integrity. The final tube diameter was determined by balancing the extruder rpm, air pressure, and take up speed with the die dimensions. The processing temperatures used in the fabrication of the tubing were:
______________________________________Temperature Profile (°F.)T1 (feed) T2 T3 T4 (die)______________________________________290 300 310 320______________________________________
The tubing was able to be heat-set into approximately a 1 inch diameter curl by looping it around or within a mandril, heating the curled tubing to 42°-50° C. (108°--122° F.) and cooling it in place. The curl, thus formed, promptly returned to its position when straightened.
The molecular weight of the BaSO4 filled terpolymer tubing was then determined. The weight average-, number average-, and Z-average molecular weights, respectively, were 260,000; 152,000; and 442,000. This demonstrated that the terpolymers can be processed to retain useful properties for applications as a stent. The tubing extrudates were of good quality - smooth, homogeneous, tough, and elastic. Preliminary results indicated that the tubing embrittled somewhat after 3 weeks in contact with aqueous fluids. Although it was still somewhat pliable, ductile failure occurred upon handling and bending. At that stage, the Mw, Mn, and Mz, respectively, were 27,600; 10,400; and 51,623. The polydispersity (Mw /Mn) was 2.65, which is a slight increase over the value of 2.0 for the unexposed terpolymer (see Table 7).
Differential scanning calorimetry indicated substantial hydrolysis and degradation. After 6-7 weeks the walls of the tubing appeared much thinner. The terpolymer tubing became softer and somewhat fibrous, and shredded easily into soft pieces.
Although the composition comprising the inventive biodegradable, biocompatible, resorbable ureteral stent has been disclosed in the context of a terpolymer of L(-)lactide, glycolide and epsilon-caprolactone, other equivalent compositions are also contemplated as being suitable compositions for preparing the stent.
Thus, it is contemplated that D(-)lactide, the internally optically inactive meso-lactide and the optically inactive racemic or D,L-lactide can be substituted for the L(-)lactide. It is also contemplated that delta-vacero-lactone can be substituted for epilson-caprolactone.
A discussion of the mechanism of biodegradation of these compounds in the form if films is disclosed in Pitt et al "Alphatic Polyesters II. The Degradation of Poly (DL-Lactide), Poly (Epilson-Caprolactone), and Their Co-Polymers In Vivo", BIOMATERIALS, pages 215-220, (Vol. II, October 1981).
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4045418 *||Jan 28, 1975||Aug 30, 1977||Gulf Oil Corporation||Copolymers of D,L-lactide and epsilon caprolactone|
|US4212304 *||Apr 7, 1978||Jul 15, 1980||Medical Engineering Corp.||Uretheral catheter stent|
|US4300565 *||Sep 26, 1980||Nov 17, 1981||American Cyanamid Company||Synthetic polyester surgical articles|
|US4379138 *||Dec 28, 1981||Apr 5, 1983||Research Triangle Institute||Biodegradable polymers of lactones|
|US4531933 *||Dec 7, 1982||Jul 30, 1985||C. R. Bard, Inc.||For maintaining drainage between the kidney and bladder|
|US4605730 *||Jun 10, 1985||Aug 12, 1986||Ethicon, Inc.||Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same|
|US4610657 *||Aug 30, 1985||Sep 9, 1986||Medical Engineering Corporation||Ureteral stent|
|US4650488 *||May 16, 1984||Mar 17, 1987||Richards Medical Company||Biodegradable prosthetic device|
|US4674506 *||Nov 29, 1984||Jun 23, 1987||Kirk Alcond||Surgical anastomosis stent|
|US4700704 *||Aug 12, 1985||Oct 20, 1987||Ethicon, Inc.||Sutures; increased tensile strength modulus|
|US4791929 *||Mar 24, 1988||Dec 20, 1988||American Cyanamid Company||Polylactone copolymer coatings; sutures; sliding|
|US4826945 *||Jun 2, 1988||May 2, 1989||Yissum Research Development Company||Biodegradable polymeric materials based on polyether glycols, processes for the preparation thereof and surgical articles made therefrom|
|US4863472 *||Sep 2, 1987||Sep 5, 1989||Biocon Oy||Bone graft implant|
|US4874360 *||Jul 1, 1988||Oct 17, 1989||Medical Engineering Corporation||Ureteral stent system|
|US4916193 *||Aug 1, 1988||Apr 10, 1990||Allied-Signal Inc.||Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides|
|US4994074 *||Feb 1, 1990||Feb 19, 1991||Ethicon, Inc.||Polylactones; high speed absorption|
|1|| *||Assimos et al, Urological Research, vol. 12, pp. 291 293 (1984).|
|2||Assimos et al, Urological Research, vol. 12, pp. 291-293 (1984).|
|3|| *||Barrows, Clinical Materials, vol. 1, pp. 233 257 (1986).|
|4||Barrows, Clinical Materials, vol. 1, pp. 233-257 (1986).|
|5|| *||Bergman et al, Investigative Urology, vol. 16, No. 1, pp. 48 49 (Jul. 1978).|
|6||Bergman et al, Investigative Urology, vol. 16, No. 1, pp. 48-49 (Jul. 1978).|
|7|| *||Flam et al, Investigative Urology, vol. 33, No. 6, pp. 490 494 (Jun. 1989).|
|8||Flam et al, Investigative Urology, vol. 33, No. 6, pp. 490-494 (Jun. 1989).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5425949 *||Jun 11, 1993||Jun 20, 1995||United States Surgical Corporation||Bioabsorbable copolymer and coating composition containing same|
|US5444113 *||Sep 29, 1993||Aug 22, 1995||Ecopol, Llc||End use applications of biodegradable polymers|
|US5489297 *||Nov 2, 1994||Feb 6, 1996||Duran; Carlos M. G.||Bioprosthetic heart valve with absorbable stent|
|US5502158 *||Sep 22, 1992||Mar 26, 1996||Ecopol, Llc||Polylactone or polylactam film, plasticizers|
|US5520631 *||Jul 22, 1994||May 28, 1996||Wound Healing Of Oklahoma||Method and apparatus for lowering the intraocular pressure of an eye|
|US5543218 *||May 15, 1995||Aug 6, 1996||United States Surgical Corporation||Bioabsorbable copolymer and coating composition containing same|
|US5562653 *||Nov 16, 1994||Oct 8, 1996||Hercules Incorporated||Polymeric implants which can depolymerize within human or animal bodies by mild heating or treatment with nontoxic chemicals for noninvasive removal|
|US5578662 *||Jun 7, 1995||Nov 26, 1996||United States Surgical Corporation||Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom|
|US5593403 *||Sep 14, 1994||Jan 14, 1997||Scimed Life Systems Inc.||Method for modifying a stent in an implanted site|
|US5599291 *||Jan 4, 1993||Feb 4, 1997||Menlo Care, Inc.||Polymer which upon hydration is capable of expanding and softening to a predetermined degree, resisting migration from ureter and facilitating urinary drainage from kidney to the bladder|
|US5629077 *||Jun 27, 1994||May 13, 1997||Advanced Cardiovascular Systems, Inc.||Mesh comprised of woven fibers heat bonded together with lower melting polymer and laminated to film; high radial strength, medical equipment, vascular systems|
|US5634946 *||Jun 7, 1995||Jun 3, 1997||Focal, Inc.||Placing solid, biocompatible, biodegradable polymeric material in contact with tissue surface, then controlled heating to fluidize polymer for coating and cooling to solidify|
|US5637113 *||Dec 13, 1994||Jun 10, 1997||Advanced Cardiovascular Systems, Inc.||Polymer film for wrapping a stent structure|
|US5650116 *||Mar 18, 1996||Jul 22, 1997||Hercules Incorporated||Method of making a medical device from ironically crosslinked polymer|
|US5662712 *||Jun 7, 1995||Sep 2, 1997||Focal, Inc.||Apparatus for intraluminal photothermoforming|
|US5670161 *||May 28, 1996||Sep 23, 1997||Healy; Kevin E.||Biodegradable stent|
|US5674287 *||Jan 14, 1994||Oct 7, 1997||Endoluminal Therapeutics, Inc.||Biodegradable polymeric endoluminal sealing process, apparatus and polymeric product for use therein|
|US5684051 *||Apr 24, 1996||Nov 4, 1997||Hercules Incorporated||Medical devices with improved elastic response|
|US5700286 *||Aug 22, 1996||Dec 23, 1997||Advanced Cardiovascular Systems, Inc.||Polymer film for wrapping a stent structure|
|US5704907 *||Dec 11, 1995||Jan 6, 1998||Wound Healing Of Oklahoma||Cellulose membrane|
|US5707385 *||Nov 16, 1994||Jan 13, 1998||Advanced Cardiovascular Systems, Inc.||Expandable sheath for delivering a therapeutic drug in a body lumen|
|US5718862 *||Apr 24, 1996||Feb 17, 1998||Hercules Incorporated||Secondary shaping of ionically crosslinked polymer compositions for medical devices|
|US5728152 *||Jun 7, 1995||Mar 17, 1998||St. Jude Medical, Inc.||Bioresorbable heart valve support|
|US5735897 *||Jan 2, 1997||Apr 7, 1998||Scimed Life Systems, Inc.||Implantable device for drug delivery|
|US5741323 *||Jun 7, 1995||Apr 21, 1998||Focal, Inc.||Polymeric article for intraluminal photothermoforming|
|US5749915 *||Jun 7, 1995||May 12, 1998||Focal, Inc.||Polymeric endoluminal paving process|
|US5749922 *||Jun 7, 1995||May 12, 1998||Endoluminal Therapeutics, Inc.||Biodegradable polymeric endoluminal sealing process, apparatus and polymeric products for use therein|
|US5760118 *||Jun 5, 1995||Jun 2, 1998||Chronopol, Inc.||Paper products|
|US5762625 *||Sep 8, 1993||Jun 9, 1998||Kabushikikaisha Igaki Iryo Sekkei||Luminal stent and device for inserting luminal stent|
|US5766710 *||Jun 19, 1996||Jun 16, 1998||Advanced Cardiovascular Systems, Inc.||Biodegradable mesh and film stent|
|US5800538 *||Jun 7, 1995||Sep 1, 1998||Endoluminal Therapeutics, Inc.||Biodegradable polymeric endoluminal sealing process|
|US5817100 *||Feb 7, 1995||Oct 6, 1998||Kabushikikaisya Igaki Iryo Sekkei||Stent device and stent supplying system|
|US5820608 *||Mar 18, 1996||Oct 13, 1998||Hercules Incorporated||Method for in vivo chemically triggered disintegration of medical device|
|US5820918 *||Jul 11, 1996||Oct 13, 1998||Hercules Incorporated||Impregnating a medical device of water absorbable polymer and medical compound, such as antiseptic or radiopaque compounds|
|US5849035 *||Apr 28, 1994||Dec 15, 1998||Focal, Inc.||Methods for intraluminal photothermoforming|
|US5895420 *||Sep 15, 1997||Apr 20, 1999||St. Jude Medical, Inc.||Bioresorbable heart valve support|
|US5925065 *||Nov 5, 1996||Jul 20, 1999||United States Surgical Corporation||Collagen material coated with moisture-retaining substance and a bioabsorbable polylactone|
|US5939191 *||Jun 23, 1997||Aug 17, 1999||United States Surgical Corporation||Bioabsorbable copolymer of a major amount of .epsilon.-caprolactone capable of being dry packaged.|
|US5957975 *||Dec 15, 1997||Sep 28, 1999||The Cleveland Clinic Foundation||Biodegradable|
|US5962007 *||Dec 19, 1997||Oct 5, 1999||Indigo Medical, Inc.||Use of a multi-component coil medical construct|
|US5980564 *||Aug 1, 1997||Nov 9, 1999||Schneider (Usa) Inc.||Bioabsorbable implantable endoprosthesis with reservoir|
|US5997568 *||Jan 17, 1997||Dec 7, 1999||United States Surgical Corporation||Absorbable polymer blends and surgical articles fabricated therefrom|
|US6001117 *||Mar 19, 1998||Dec 14, 1999||Indigo Medical, Inc.||Bellows medical construct and apparatus and method for using same|
|US6045568 *||Feb 5, 1997||Apr 4, 2000||Igaki; Keiji||Luminal stent, holding structure therefor and device for attaching luminal stent|
|US6060534 *||Jul 11, 1996||May 9, 2000||Scimed Life Systems, Inc.||Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties|
|US6080177 *||Apr 28, 1998||Jun 27, 2000||Igaki; Keiji||Luminal stent, holding structure therefor and device for attaching luminal stent|
|US6096018 *||Aug 3, 1998||Aug 1, 2000||Scimed Life Systems, Inc.||Medical treatment utilizing ionically crosslinked medical devices|
|US6102045 *||Dec 24, 1997||Aug 15, 2000||Premier Laser Systems, Inc.||Method and apparatus for lowering the intraocular pressure of an eye|
|US6174330||Aug 1, 1997||Jan 16, 2001||Schneider (Usa) Inc||Bioabsorbable marker having radiopaque constituents|
|US6176871||Oct 14, 1998||Jan 23, 2001||Focal, Inc.||Apparatus and methods for intraluminal photothermoforming|
|US6177094||Jan 29, 1999||Jan 23, 2001||United States Surgical Corporation||Bioabsorbable blends and coating composition containing same|
|US6184266||Feb 2, 2000||Feb 6, 2001||Scimed Life Systems, Inc.||Providing crosslinkable polymer, crosslinking crosslinkable polymerand shaping crosslinked polymer to form device; deforming by crosslinking|
|US6186985||Oct 3, 1997||Feb 13, 2001||Boston Scientific Corporation||Gastro-intestinal tube with dissolvable support bolster|
|US6207767||Nov 26, 1997||Mar 27, 2001||United States Surgical Corporation||Bioabsorbable branched polymer containing units derived from dioxanone and medical/surgical devices manufactured therefrom|
|US6228111||Sep 27, 1996||May 8, 2001||Bionx Implants Oy||First and second degradation and detaching times over longitudinal axis|
|US6245103||Aug 1, 1997||Jun 12, 2001||Schneider (Usa) Inc||Bioabsorbable self-expanding stent|
|US6251135 *||Mar 8, 1999||Jun 26, 2001||Schneider (Usa) Inc||Radiopaque marker system and method of use|
|US6251136||Dec 8, 1999||Jun 26, 2001||Advanced Cardiovascular Systems, Inc.||Method of layering a three-coated stent using pharmacological and polymeric agents|
|US6258122||Feb 5, 1997||Jul 10, 2001||St. Jude Medical, Inc.||Bioresorbable annuloplasty prosthesis|
|US6312474||Sep 15, 1999||Nov 6, 2001||Bio-Vascular, Inc.||Resorbable implant materials|
|US6323307||Aug 16, 1995||Nov 27, 2001||Cargill Dow Polymers, Llc||Biodegradable film, foam, coating, or molded article, but can also be an extruded article, nonwoven fiber, pellet, powder, laminate or adhesives comprising lactide polymer|
|US6334868||Oct 8, 1999||Jan 1, 2002||Advanced Cardiovascular Systems, Inc.||Stent cover|
|US6340367||Aug 1, 1997||Jan 22, 2002||Boston Scientific Scimed, Inc.||Radiopaque markers and methods of using the same|
|US6356782||Apr 2, 1999||Mar 12, 2002||Vivant Medical, Inc.||Subcutaneous cavity marking device and method|
|US6368346||Jun 3, 1999||Apr 9, 2002||American Medical Systems, Inc.||Bioresorbable stent|
|US6368356||Feb 25, 2000||Apr 9, 2002||Scimed Life Systems, Inc.||Medical devices comprising hydrogel polymers having improved mechanical properties|
|US6371904||Jul 2, 1999||Apr 16, 2002||Vivant Medical, Inc.||Subcutaneous cavity marking device and method|
|US6387978||Jan 8, 2001||May 14, 2002||Boston Scientific Corporation||Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties|
|US6443941||Jul 24, 2000||Sep 3, 2002||Endoluminal Therapeutics, Inc.||Introducing polycaprolactone pliable tube containing living cells into lumen of diseased organ; chemical or physical reconfiguration to mold polymer to wall of cavity; preventing abrupt reclosure or restenosis postangioplasty|
|US6464723||Apr 22, 1999||Oct 15, 2002||Advanced Cardiovascular Systems, Inc.||Radiopaque stents|
|US6527801||Apr 13, 2000||Mar 4, 2003||Advanced Cardiovascular Systems, Inc.||Biodegradable drug delivery material for stent|
|US6548569||Mar 24, 2000||Apr 15, 2003||Metabolix, Inc.||Biodegradable polyhydroxyalkanoate; orthopedics, surgery|
|US6569081||Feb 10, 2000||May 27, 2003||Coloplast A/S||Ostomy plug|
|US6585757||Sep 15, 1999||Jul 1, 2003||Advanced Cardiovascular Systems, Inc.||Endovascular stent with radiopaque spine|
|US6602287||Dec 8, 1999||Aug 5, 2003||Advanced Cardiovascular Systems, Inc.||Preventing coagulation on surfaces of graft medical equipment by applying coatings such as octafluoropropane and overcoatings comprising artery and/or vein cell lining mimetics|
|US6605114||Oct 29, 1999||Aug 12, 2003||Advanced Cardiovascular Systems, Inc.||Bonding with implantable stent with attractant coating; preventing coagulation|
|US6652594||Mar 14, 2002||Nov 25, 2003||Synovis Life Technologies, Inc.||Resorbable implant materials|
|US6699272||Dec 13, 2001||Mar 2, 2004||Endoluminal Therapeutics, Inc.||Biodegradable polymeric endoluminal sealing process, apparatus and polymeric products for use therein|
|US6702849||Dec 13, 1999||Mar 9, 2004||Advanced Cardiovascular Systems, Inc.||Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers|
|US6740731 *||Feb 12, 2001||May 25, 2004||Cargill Dow Polymers Llc||Comprising a hydroxycarboxylic acid-containing polymer where the polymer biodegrades hydrolytically during storage, use and disposal stages in a controlled manner,the rate being accelerated during disposal; microbiocides|
|US6747121||Sep 5, 2001||Jun 8, 2004||Synthes (Usa)||Poly(L-lactide-co-glycolide) copolymers, methods for making and using same, and devices containing same|
|US6776792||Apr 24, 1997||Aug 17, 2004||Advanced Cardiovascular Systems Inc.||Body implantable within lumen of vascular system, with coating devoid of heparin exclusively deposited on surfaces incapable of contacting vessel walls, made of material that adheres to body and has functional groups attracting and bonding heparin|
|US6838493||Feb 26, 2002||Jan 4, 2005||Metabolix, Inc.||Biocompatible with controlled degradation rates|
|US6867247||May 1, 2002||Mar 15, 2005||Metabolix, Inc.||Biocompatibility|
|US6887266||Jan 15, 2003||May 3, 2005||Synecor, Llc||Endoprostheses and methods of manufacture|
|US6913765||Mar 21, 2001||Jul 5, 2005||Scimed Life Systems, Inc.||Controlling resorption of bioresorbable medical implant material|
|US6929663||Mar 26, 2003||Aug 16, 2005||Boston Scientific Scimed, Inc.||Longitudinally expanding medical device|
|US6932930||Nov 4, 2003||Aug 23, 2005||Synecor, Llc||Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same|
|US6991647||Jan 31, 2001||Jan 31, 2006||Ams Research Corporation||A biocompatible tube shapes, made from a blends of polycaprolactone and polylactic acid; high molecular weight polymers; wounded monofilament wovens; prevent restenosis disorders; stable, nondecomposing|
|US7044957||Feb 2, 2001||May 16, 2006||Ethicon Endo-Surgery, Inc.||Devices for defining and marking tissue|
|US7077860||Jun 24, 2004||Jul 18, 2006||Advanced Cardiovascular Systems, Inc.||Medical insert coated with compound that bonds to heparin|
|US7097907||Jul 30, 2003||Aug 29, 2006||United States Surgical Corporation||polydioxanone star polymers used as as fiber coatings, bioadhesives, tissue growth substrate or bone fusion devices|
|US7105018||Dec 30, 2002||Sep 12, 2006||Advanced Cardiovascular Systems, Inc.||Drug-eluting stent cover and method of use|
|US7108716||Sep 30, 2003||Sep 19, 2006||Schneider (Usa) Inc.||Stent-graft with bioabsorbable structural support|
|US7141061||Jan 15, 2003||Nov 28, 2006||Synecor, Llc||Photocurable endoprosthesis system|
|US7144422||Nov 13, 2002||Dec 5, 2006||Advanced Cardiovascular Systems, Inc.||Drug-eluting stent and methods of making the same|
|US7144588||Jan 17, 2003||Dec 5, 2006||Synovis Life Technologies, Inc.||tissue surfaces and/or surgical articles involved in the surgery are separated by a biomaterial provided in the form of a non-crosslinked, decellularized and purified mammalian tissue (e.g. bovine pericardium)|
|US7163715||Dec 30, 2002||Jan 16, 2007||Advanced Cardiovascular Systems, Inc.||Spray processing of porous medical devices|
|US7179289||Jun 7, 2004||Feb 20, 2007||Conor Medsystems, Inc.||Expandable medical device for delivery of beneficial agent|
|US7179883||Dec 22, 2004||Feb 20, 2007||Metabolix, Inc.||Biocompatibility; biopolymers such as poly-4-hydroxybutyrate, poly-4-hydroxybutyrate-co-3-hydroxybutyrate, poly-4-hydroxybutyrate-co-2-hydroxybutyrate, and copolymers and blends; controlled degradation rate; grafting|
|US7186789||Jun 11, 2003||Mar 6, 2007||Advanced Cardiovascular Systems, Inc.||nonfouling surfaces; block copolyesters having a biobeneficial moiety that provides a biological benefit without releasing pharmaceutically active agent; condensation polymerization|
|US7201940||Jun 12, 2001||Apr 10, 2007||Advanced Cardiovascular Systems, Inc.||Method and apparatus for thermal spray processing of medical devices|
|US7229417||Oct 15, 2004||Jun 12, 2007||Ethicon Endo-Surgery, Inc.||Methods for marking a biopsy site|
|US7229471||Sep 10, 2004||Jun 12, 2007||Advanced Cardiovascular Systems, Inc.||Compositions containing fast-leaching plasticizers for improved performance of medical devices|
|US7268205||Jan 16, 2007||Sep 11, 2007||Metabolix, Inc.||Medical devices and applications of polyhydroxyalkanoate polymers|
|US7285125||Oct 5, 2005||Oct 23, 2007||Tyco Healthcare Group Lp||Compression anastomosis device and method|
|US7285287||Sep 15, 2003||Oct 23, 2007||Synecor, Llc||Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses|
|US7285304||Jun 25, 2003||Oct 23, 2007||Advanced Cardiovascular Systems, Inc.||Coating the device with a polymer, an active agent and a solvent; evaporating the solvent; and applying a polymer-free fluid to the dry coating to increase the crystallinity of the polymer|
|US7291166||May 18, 2005||Nov 6, 2007||Advanced Cardiovascular Systems, Inc.||Polymeric stent patterns|
|US7297758||Aug 2, 2005||Nov 20, 2007||Advanced Cardiovascular Systems, Inc.||Method for extending shelf-life of constructs of semi-crystallizable polymers|
|US7301001||Dec 20, 2006||Nov 27, 2007||Advanced Cardiovascular Systems, Inc.||Bioabsorbable, biobeneficial polyester polymers for stent coatings|
|US7312299||Dec 20, 2006||Dec 25, 2007||Advanced Cardiovascular Systems, Inc.||Nonfouling surfaces; block copolyesters having a biobeneficial moiety that provides a biological benefit without releasing pharmaceutically active agent; condensation polymerization; for medical implants|
|US7321008||Aug 28, 2006||Jan 22, 2008||United States Surgical Corporation||Bioabsorbable branched polymers end-capped with diketene acetals|
|US7329366||Jun 18, 2004||Feb 12, 2008||Advanced Cardiovascular Systems Inc.||Method of polishing implantable medical devices to lower thrombogenecity and increase mechanical stability|
|US7335375||Jun 21, 2005||Feb 26, 2008||Boston Scientific Scimed, Inc.||Controlling resorption of bioresorbable medical implant material|
|US7351421||Mar 26, 2004||Apr 1, 2008||Hsing-Wen Sung||Drug-eluting stent having collagen drug carrier chemically treated with genipin|
|US7381048||Apr 12, 2005||Jun 3, 2008||Advanced Cardiovascular Systems, Inc.||Stents with profiles for gripping a balloon catheter and molds for fabricating stents|
|US7390333||Jan 10, 2003||Jun 24, 2008||Advanced Cardiovascular Systems, Inc.||Biodegradable drug delivery material for stent|
|US7402320||Aug 26, 2005||Jul 22, 2008||Vnus Medical Technologies, Inc.||Apparatus, material compositions, and methods for permanent occlusion of a hollow anatomical structure|
|US7410498||Jun 26, 2001||Aug 12, 2008||Pentech Medical Devices Ltd.||Polymeric stents and other surgical articles|
|US7413574||Aug 1, 2006||Aug 19, 2008||Advanced Cardiovascular Systems, Inc.||Drug-eluting stent cover method of use|
|US7416558||Aug 1, 2006||Aug 26, 2008||Advanced Cardiovascular Systems, Inc.||Drug-eluting stent cover and method of use|
|US7435255||Sep 22, 2003||Oct 14, 2008||Advnaced Cardiovascular Systems, Inc.||Drug-eluting stent and methods of making|
|US7470283||Jan 10, 2003||Dec 30, 2008||Advanced Cardiovascular Systems, Inc.||Biodegradable drug delivery material for stent|
|US7476245||Aug 16, 2005||Jan 13, 2009||Advanced Cardiovascular Systems, Inc.||Polymeric stent patterns|
|US7514122||Oct 17, 2006||Apr 7, 2009||Advanced Cardiovascular Systems, Inc.||Coating a consolidated biocompatible medical device such as a stent by directing a supersonic jet of high pressure gas and particles to form a functionally graded coating to allow direct control of drug elution without an additional polymer topcoat; applying a drug to the coating|
|US7553325||Aug 6, 2003||Jun 30, 2009||Boston Scientific Scimed, Inc.||Bioabsorbable marker having radiopaque constituents|
|US7553923||Oct 26, 2007||Jun 30, 2009||Metabolix, Inc.||Medical devices and applications of polyhydroxyalkanoate polymers|
|US7569076||Mar 21, 2003||Aug 4, 2009||Children's Medical Center Corporation||An implantable, biocompatible, synthetic/natural, polymer matrix structure shaped like a bladder having the matrix coated with biodegradable shape-setting, liquefied glycolic acid-lactic acid copolymer and cells deposited on/in the matrix to form an organized matrix/cell graft repair or replacement|
|US7582110||Apr 11, 2005||Sep 1, 2009||Cook Incorporated||Implantable frame with variable compliance|
|US7622070||Jun 20, 2005||Nov 24, 2009||Advanced Cardiovascular Systems, Inc.||Tubing-mandrels; stents|
|US7625397||Sep 18, 2001||Dec 1, 2009||Ethicon Endo-Surgery, Inc.||Methods for defining and marking tissue|
|US7641825||Jul 29, 2005||Jan 5, 2010||Tepha, Inc.||Method of making a polyhydroxyalkanoate filament|
|US7658880||Jul 29, 2005||Feb 9, 2010||Advanced Cardiovascular Systems, Inc.||Polymeric stent polishing method and apparatus|
|US7662326||Apr 27, 2007||Feb 16, 2010||Advanced Cardiovascular Systems, Inc.||Compositions containing fast-leaching plasticizers for improved performance of medical devices|
|US7668582||Oct 7, 2004||Feb 23, 2010||Ethicon Endo-Surgery, Inc.||Biopsy site marker|
|US7699887||Aug 2, 2006||Apr 20, 2010||Boston Scientific Scimed, Inc.||Stent-graft with bioabsorbable structural support|
|US7699890||Jan 28, 2004||Apr 20, 2010||Advanced Cardiovascular Systems, Inc.||Medicated porous metal prosthesis and a method of making the same|
|US7708548||Apr 10, 2008||May 4, 2010||Advanced Cardiovascular Systems, Inc.||Molds for fabricating stents with profiles for gripping a balloon catheter|
|US7713308||Sep 14, 2007||May 11, 2010||Boston Scientific Scimed, Inc.||Stent with soluble bladder retention member|
|US7731890||Jun 15, 2006||Jun 8, 2010||Advanced Cardiovascular Systems, Inc.||conveying a gas into a poly(L-lactide) tube disposed within a cylindrical mold to increase pressure inside tube, wherein increased pressure radially expands tube to conform to inside surface of the mold, applying tension along axis of the tube to axially extend tube, fabricating stent from expanded tube|
|US7740791||Jun 30, 2006||Jun 22, 2010||Advanced Cardiovascular Systems, Inc.||Method of fabricating a stent with features by blow molding|
|US7757543||Jul 13, 2006||Jul 20, 2010||Advanced Cardiovascular Systems, Inc.||Radio frequency identification monitoring of stents|
|US7758631||Nov 25, 2003||Jul 20, 2010||Boston Scientific Scimed, Inc.||Bioabsorbable endoprosthesis having elongate axial reservoir for by-product collection|
|US7758881||Mar 24, 2005||Jul 20, 2010||Advanced Cardiovascular Systems, Inc.||stents having everolimus and clobetasol; restenosis, vulnerable plaque; biodegradable|
|US7761968||May 25, 2006||Jul 27, 2010||Advanced Cardiovascular Systems, Inc.||Method of crimping a polymeric stent|
|US7794495 *||Jul 17, 2006||Sep 14, 2010||Advanced Cardiovascular Systems, Inc.||A stent having a structural element made of a polymer with a hydrolytically degradable L-lactide block and a polystyrenesulfonate or poly(2-acrylamido-2-methylpropanesulfonic acid) block in which the acid group is protecting group; when deprotected the acid group initiates degradation|
|US7794776||Jun 29, 2006||Sep 14, 2010||Abbott Cardiovascular Systems Inc.||modifying molecular weight, comprises polyester amide coating; improving degradation rate and drug release rate|
|US7811332||Jul 22, 2005||Oct 12, 2010||Children's Medical Center Corporation||Reconstruction method for urological structures utilizing polymeric matrices|
|US7819912||Mar 4, 2003||Oct 26, 2010||Innovational Holdings Llc||Expandable medical device with beneficial agent delivery mechanism|
|US7820732 *||Apr 30, 2004||Oct 26, 2010||Advanced Cardiovascular Systems, Inc.||reacting a poly(ester amide), poly(glycerol sebacic acid), or a low Tg PolyAspirin with a aromatic diol chemical stiffening agent to form a higher glass transition temperature polymer, and using that to coat an implantable medical device such as a stent; cancer or stenosis|
|US7823263||Jul 9, 2007||Nov 2, 2010||Abbott Cardiovascular Systems Inc.||Method of removing stent islands from a stent|
|US7829008||May 30, 2007||Nov 9, 2010||Abbott Cardiovascular Systems Inc.||Fabricating a stent from a blow molded tube|
|US7833260||Jul 20, 2007||Nov 16, 2010||Orbusneich Medical, Inc.||Bioabsorbable polymeric medical device|
|US7837645||Mar 5, 2007||Nov 23, 2010||The Trustees Of Columbia University In The City Of New York||Endoscopic gastric bypass|
|US7842083||Feb 27, 2006||Nov 30, 2010||Innovational Holdings, Llc.||Expandable medical device with improved spatial distribution|
|US7842098||Jun 22, 2005||Nov 30, 2010||Boston Scientific Scimed, Inc.||Longitudinally expanding medical device|
|US7842737||Sep 29, 2006||Nov 30, 2010||Abbott Cardiovascular Systems Inc.||Polymer blend-bioceramic composite implantable medical devices|
|US7846197||Jul 20, 2007||Dec 7, 2010||Orbusneich Medical, Inc.||Bioabsorbable polymeric medical device|
|US7846361||Jul 20, 2007||Dec 7, 2010||Orbusneich Medical, Inc.||Bioabsorbable polymeric composition for a medical device|
|US7850727||Nov 14, 2005||Dec 14, 2010||Innovational Holdings, Llc||Expandable medical device for delivery of beneficial agent|
|US7850728||Mar 6, 2006||Dec 14, 2010||Innovational Holdings Llc||Expandable medical device for delivery of beneficial agent|
|US7875233||Jul 18, 2005||Jan 25, 2011||Advanced Cardiovascular Systems, Inc.||Method of fabricating a biaxially oriented implantable medical device|
|US7875283||Jun 16, 2005||Jan 25, 2011||Advanced Cardiovascular Systems, Inc.||A stent coated with hydrophobic polymer having water-labile bonds and strength to withstand forces of the vascular systems and also biodegrades on its surface rather than bulk erosion; mechanical properties; drug delivery; a polyester,-anhydride or -amide having the monomer, trimellitylimidotyrosine|
|US7886419||Jul 18, 2006||Feb 15, 2011||Advanced Cardiovascular Systems, Inc.||Stent crimping apparatus and method|
|US7896912||Apr 13, 2004||Mar 1, 2011||Innovational Holdings, Llc||Expandable medical device with S-shaped bridging elements|
|US7901452||Jun 27, 2007||Mar 8, 2011||Abbott Cardiovascular Systems Inc.||Method to fabricate a stent having selected morphology to reduce restenosis|
|US7910125||Feb 26, 2008||Mar 22, 2011||Boston Scientific Scimed, Inc.||With embedded particles having magnetic or (super)paramagnetic properties in the bulk material; modulating swelling, hydrolysis, or movement of the particles with microwaves, ultrasonic or radio frequencies; time-release agents|
|US7919162 *||Jun 7, 2005||Apr 5, 2011||Synecor, Llc||Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same|
|US7923022||Sep 13, 2006||Apr 12, 2011||Advanced Cardiovascular Systems, Inc.||stent body is made of polylactone copolymer consisting of monomers selected from lactic acid, glycolic acid and hydroxyhexanoic acid; copolymerized in solvent; mechanical stability, nonbrittleness, fracturing resist|
|US7927529||Oct 2, 2008||Apr 19, 2011||Cordis Corporation||Method of forming bioabsorbable drug delivery devices|
|US7943683||Oct 31, 2007||May 17, 2011||Tepha, Inc.||Thin bioabsorbable materials; toughness, low modulus, tensile strength; tissue repair, drug delivery and support; solvent casting or melt extrusion continuous production|
|US7951185||Jan 6, 2006||May 31, 2011||Advanced Cardiovascular Systems, Inc.||Delivery of a stent at an elevated temperature|
|US7951194||May 22, 2007||May 31, 2011||Abbott Cardiovascular Sysetms Inc.||Bioabsorbable stent with radiopaque coating|
|US7955381||Jun 29, 2007||Jun 7, 2011||Advanced Cardiovascular Systems, Inc.||Polymer-bioceramic composite implantable medical device with different types of bioceramic particles|
|US7959857||Jun 1, 2007||Jun 14, 2011||Abbott Cardiovascular Systems Inc.||Radiation sterilization of medical devices|
|US7959940||May 30, 2006||Jun 14, 2011||Advanced Cardiovascular Systems, Inc.||Polymer-bioceramic composite implantable medical devices|
|US7959942||Oct 20, 2007||Jun 14, 2011||Orbusneich Medical, Inc.||Bioabsorbable medical device with coating|
|US7964210||Mar 31, 2006||Jun 21, 2011||Abbott Cardiovascular Systems Inc.||Degradable polymeric implantable medical devices with a continuous phase and discrete phase|
|US7967998||Jan 3, 2008||Jun 28, 2011||Advanced Cardiocasvular Systems, Inc.||Method of polishing implantable medical devices to lower thrombogenecity and increase mechanical stability|
|US7971333||May 30, 2006||Jul 5, 2011||Advanced Cardiovascular Systems, Inc.||Manufacturing process for polymetric stents|
|US7972354||Jan 25, 2006||Jul 5, 2011||Tyco Healthcare Group Lp||Method and apparatus for impeding migration of an implanted occlusive structure|
|US7972373||Dec 19, 2007||Jul 5, 2011||Advanced Technologies And Regenerative Medicine, Llc||Balloon expandable bioabsorbable stent with a single stress concentration region interconnecting adjacent struts|
|US7989018||Mar 31, 2006||Aug 2, 2011||Advanced Cardiovascular Systems, Inc.||Fluid treatment of a polymeric coating on an implantable medical device|
|US7998404||Jul 13, 2006||Aug 16, 2011||Advanced Cardiovascular Systems, Inc.||Reduced temperature sterilization of stents|
|US8007529||Aug 1, 2008||Aug 30, 2011||Advanced Cardiovascular Systems, Inc.||Medicated porous metal prosthesis|
|US8011370||Dec 19, 2008||Sep 6, 2011||Tyco Healthcare Group Lp||Method for permanent occlusion of fallopian tube|
|US8016879||Jun 27, 2007||Sep 13, 2011||Abbott Cardiovascular Systems Inc.||Drug delivery after biodegradation of the stent scaffolding|
|US8034270||Apr 30, 2004||Oct 11, 2011||Tepha, Inc.||Absorbable polyesters; surgery meshes|
|US8034287||May 15, 2007||Oct 11, 2011||Abbott Cardiovascular Systems Inc.||Radiation sterilization of medical devices|
|US8043553||Sep 30, 2004||Oct 25, 2011||Advanced Cardiovascular Systems, Inc.||Controlled deformation of a polymer tube with a restraining surface in fabricating a medical article|
|US8052734||Jun 13, 2008||Nov 8, 2011||Innovational Holdings, Llc||Expandable medical device with beneficial agent delivery mechanism|
|US8052735||Jun 16, 2008||Nov 8, 2011||Innovational Holdings, Llc||Expandable medical device with ductile hinges|
|US8084125||Dec 11, 2009||Dec 27, 2011||Tepha, Inc.||Non-curling polyhydroxyalkanoate sutures|
|US8099849||Dec 13, 2006||Jan 24, 2012||Abbott Cardiovascular Systems Inc.||Optimizing fracture toughness of polymeric stent|
|US8109948||Jul 13, 2007||Feb 7, 2012||Tyco Healthcare Group Lp||Compression anastomosis device and method|
|US8109994||Jan 2, 2008||Feb 7, 2012||Abbott Cardiovascular Systems, Inc.||Biodegradable drug delivery material for stent|
|US8128682||May 11, 2010||Mar 6, 2012||Cook Medical Technologies Llc||Medical device with tensionably attached remodelable material|
|US8128687||Aug 25, 2006||Mar 6, 2012||Advanced Cardiovascular Systems, Inc.||Drug-eluting stent with filament strands|
|US8128688||Jun 19, 2007||Mar 6, 2012||Abbott Cardiovascular Systems Inc.||Carbon coating on an implantable device|
|US8128707||May 20, 2009||Mar 6, 2012||Children's Medical Center Corporation||Bladder reconstruction|
|US8172897||Jun 28, 2004||May 8, 2012||Advanced Cardiovascular Systems, Inc.||Polymer and metal composite implantable medical devices|
|US8173062||Sep 30, 2004||May 8, 2012||Advanced Cardiovascular Systems, Inc.||Controlled deformation of a polymer tube in fabricating a medical article|
|US8187321||Sep 7, 2005||May 29, 2012||Innovational Holdings, Llc||Expandable medical device for delivery of beneficial agent|
|US8202528||Jun 5, 2007||Jun 19, 2012||Abbott Cardiovascular Systems Inc.||Implantable medical devices with elastomeric block copolymer coatings|
|US8241554||Jun 29, 2004||Aug 14, 2012||Advanced Cardiovascular Systems, Inc.||Method of forming a stent pattern on a tube|
|US8241657||Dec 4, 2008||Aug 14, 2012||Boston Scientific Scimed, Inc.||Biodisintegrable medical devices|
|US8246690||Mar 25, 2010||Aug 21, 2012||Boston Scientific Scimed, Inc.||Stent with soluble bladder retention member|
|US8252064||Feb 2, 2006||Aug 28, 2012||Poly-Med, Inc.||Fiber-reinforced composite absorbable endoureteral stent|
|US8262695||Jan 25, 2006||Sep 11, 2012||Tyco Healthcare Group Lp||Structures for permanent occlusion of a hollow anatomical structure|
|US8262723||Apr 9, 2007||Sep 11, 2012||Abbott Cardiovascular Systems Inc.||Implantable medical devices fabricated from polymer blends with star-block copolymers|
|US8267990||Aug 31, 2010||Sep 18, 2012||Advanced Cardiovascular Systems, Inc.||Controlled degradation of stents|
|US8277391||Aug 7, 2002||Oct 2, 2012||Devicor Medical Products, Inc.||Methods and devices for defining and marking tissue|
|US8292822||May 4, 2004||Oct 23, 2012||Devicor Medical Products, Inc.||Biopsy localization method and device|
|US8293260||Jun 5, 2007||Oct 23, 2012||Abbott Cardiovascular Systems Inc.||Elastomeric copolymer coatings containing poly (tetramethyl carbonate) for implantable medical devices|
|US8298466||Jun 27, 2008||Oct 30, 2012||Abbott Cardiovascular Systems Inc.||Method for fabricating medical devices with porous polymeric structures|
|US8306602||Sep 30, 2005||Nov 6, 2012||Devicor Medical Products, Inc.||Biopsy cavity marking device|
|US8318195||Dec 3, 2010||Nov 27, 2012||Boston Scientific Scimed, Inc.||Controlling resorption of bioresorbable medical implant material by application of microwave, ultrasound or radiofrequencies|
|US8318484||Nov 12, 2009||Nov 27, 2012||Tengion, Inc.||Isolated renal cells and uses thereof|
|US8320993||Mar 13, 2001||Nov 27, 2012||Devicor Medical Products, Inc.||Subcutaneous cavity marking device|
|US8320994||Oct 6, 2004||Nov 27, 2012||Devicor Medical Products, Inc.||Biopsy cavity marking device and method|
|US8328877||Mar 19, 2002||Dec 11, 2012||Boston Scientific Scimed, Inc.||Stent retention element and related methods|
|US8333000||Jun 19, 2006||Dec 18, 2012||Advanced Cardiovascular Systems, Inc.||Methods for improving stent retention on a balloon catheter|
|US8333201||Jul 1, 2011||Dec 18, 2012||Covidien Lp||Method for permanent occlusion of fallopian tube|
|US8333786||Oct 18, 2010||Dec 18, 2012||Covidien Lp||Method and apparatus for implanting an occlusive structure|
|US8343530||Dec 22, 2006||Jan 1, 2013||Abbott Cardiovascular Systems Inc.||Polymer-and polymer blend-bioceramic composite implantable medical devices|
|US8403943||Aug 6, 2007||Mar 26, 2013||Howmedica Osteonics Corp.||Insertion system for implanting a medical device and surgical methods|
|US8414642||Dec 1, 2008||Apr 9, 2013||Advanced Cardiovascular Systems, Inc.||Biodegradable stent of a polyorthoester polymer or a polyanhydride polymer|
|US8425591||Jun 11, 2007||Apr 23, 2013||Abbott Cardiovascular Systems Inc.||Methods of forming polymer-bioceramic composite medical devices with bioceramic particles|
|US8435550||Aug 13, 2008||May 7, 2013||Abbot Cardiovascular Systems Inc.||Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device|
|US8439968||Mar 22, 2011||May 14, 2013||Innovational Holdings, Llc||Expandable medical device for delivery of beneficial agent|
|US8460362||Jul 20, 2007||Jun 11, 2013||Orbusneich Medical, Inc.||Bioabsorbable polymeric medical device|
|US8460364||Jul 20, 2007||Jun 11, 2013||Orbusneich Medical, Inc.||Bioabsorbable polymeric medical device|
|US8470014||Aug 14, 2007||Jun 25, 2013||Advanced Cardiovascular Systems, Inc.||Stent-catheter assembly with a releasable connection for stent retention|
|US8486135||Apr 9, 2007||Jul 16, 2013||Abbott Cardiovascular Systems Inc.||Implantable medical devices fabricated from branched polymers|
|US8496865 *||Oct 15, 2010||Jul 30, 2013||Abbott Cardiovascular Systems Inc.||Method to minimize chain scission and monomer generation in processing of poly(L-lactide) stent|
|US8500947||Oct 27, 2008||Aug 6, 2013||Covidien Lp||Speeding cure rate of bioadhesives|
|US8535372||Jun 18, 2007||Sep 17, 2013||Abbott Cardiovascular Systems Inc.||Bioabsorbable stent with prohealing layer|
|US8545869||Nov 26, 2012||Oct 1, 2013||Boston Scientific Scimed, Inc.||Controlling resorption of bioresorbable medical implant material through dispersed responsive particles|
|US8568469||Jun 28, 2004||Oct 29, 2013||Advanced Cardiovascular Systems, Inc.||Stent locking element and a method of securing a stent on a delivery system|
|US8585754||Jan 13, 2012||Nov 19, 2013||Abbott Cardiovascular Systems Inc.||Stent formed of a Biodegradable material|
|US8600481||Sep 5, 2012||Dec 3, 2013||Devicor Medical Products, Inc.||Subcutaneous cavity marking device|
|US8661630||May 21, 2008||Mar 4, 2014||Abbott Cardiovascular Systems Inc.||Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer|
|US8691321||Oct 20, 2007||Apr 8, 2014||Orbusneich Medical, Inc.||Bioabsorbable polymeric composition and medical device background|
|US8697110 *||May 14, 2009||Apr 15, 2014||Abbott Cardiovascular Systems Inc.||Polymers comprising amorphous terpolymers and semicrystalline blocks|
|US8697113 *||May 14, 2009||Apr 15, 2014||Abbott Cardiovascular Systems Inc.||Coating comprising a terpolymer comprising caprolactone and glycolide|
|US8703038||Jul 19, 2013||Apr 22, 2014||Abbott Cardiovascular Systems Inc.||Method to minimize chain scission and monomer generation in processing of poly(L-lactide) stent|
|US8747878||Apr 28, 2006||Jun 10, 2014||Advanced Cardiovascular Systems, Inc.||Method of fabricating an implantable medical device by controlling crystalline structure|
|US8747879||May 31, 2006||Jun 10, 2014||Advanced Cardiovascular Systems, Inc.||Method of fabricating an implantable medical device to reduce chance of late inflammatory response|
|US8752267||Aug 9, 2013||Jun 17, 2014||Abbott Cardiovascular Systems Inc.||Method of making stents with radiopaque markers|
|US8752268||Aug 9, 2013||Jun 17, 2014||Abbott Cardiovascular Systems Inc.||Method of making stents with radiopaque markers|
|US8753555||Apr 11, 2011||Jun 17, 2014||Tepha, Inc.||Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers|
|US8758657||Jul 16, 2013||Jun 24, 2014||Tepha, Inc.||Process of making polyhydroxyalkanoate medical textiles|
|US8778256||Sep 30, 2004||Jul 15, 2014||Advanced Cardiovascular Systems, Inc.||Deformation of a polymer tube in the fabrication of a medical article|
|US20100209476 *||May 14, 2009||Aug 19, 2010||Abbott Cardiovascular Systems Inc.||Coating comprising a terpolymer comprising caprolactone and glycolide|
|US20110153000 *||Mar 4, 2011||Jun 23, 2011||Howmedica Osteonics Corp.||Non-destructive tissue repair and regeneration|
|US20120091633 *||Oct 15, 2010||Apr 19, 2012||Yunbing Wang||Method To Minimize Chain Scission And Monomer Generation In Processing of Poly(L-Lactide) Stent|
|USRE38653 *||Nov 5, 2002||Nov 16, 2004||Kabushikikaisha Igaki Iryo Sekkei||Luminal stent, holding structure therefor and device for attaching luminal stent|
|USRE38711 *||Nov 5, 2002||Mar 15, 2005||Kabushikikaisha Igaki Iryo Sekkei||Luminal stent, holding structure therefor and device for attaching luminal stent|
|EP0894503A2 *||Jun 8, 1998||Feb 3, 1999||Schneider (Usa) Inc.,||Bioabsorbable marker having radiopaque constituents and method of using same|
|EP1304085A2 *||Sep 12, 1995||Apr 23, 2003||Ethicon Endo-Surgery, Inc.||Biodegradable tissue marking device|
|EP1415671A1||Nov 1, 2002||May 6, 2004||Polyganics B.V.||Biodegradable drains for medical applications|
|EP1837042A2 *||Feb 15, 2007||Sep 26, 2007||Cordis Corporation||Implantable device formed from polymer blends having modified molecular structures|
|EP1848369A2 *||Feb 2, 2006||Oct 31, 2007||Poly-Med, Inc.||Fiber-reinforced composite absorbable endoureteral stent|
|EP1973586A2 *||Jan 8, 2007||Oct 1, 2008||Cordis Corporation||Bioabsorbable drug delivery devices|
|EP2036582A1||Jul 21, 1995||Mar 18, 2009||United States Surgical Corporation||Biobsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom|
|EP2301597A1||Jul 21, 1995||Mar 30, 2011||United States Surgical Corporation||Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom|
|EP2308522A2||Nov 17, 2000||Apr 13, 2011||Boston Scientific Limited||Microfabricated devices for the delivery of molecules into a carrier fluid|
|EP2559408A2||Oct 24, 2007||Feb 20, 2013||Biosensors International Group, Ltd.||Temporary intraluminal stent and methods of manufacture and use.|
|EP2634198A1||Dec 27, 2012||Sep 4, 2013||Suntech Co., Ltd.||Copolymers containing phosphorylcholine groups and methods of preparing and using the same|
|WO1993015787A1 *||Feb 12, 1993||Aug 19, 1993||Jerry W Chandler||Biodegradable stent|
|WO1998002114A1 *||Jun 30, 1997||Jan 22, 1998||Hercules Inc||Medical devices containing in-situ generated medical compounds|
|WO1998002204A1 *||Jun 30, 1997||Jan 22, 1998||Hercules Inc||Medical devices comprising ionically and non-ionically cross-linked polymer hydrogels having improved mechanical properties|
|WO2003020330A2 *||Sep 4, 2002||Mar 13, 2003||Sylwester Gogolewski||Poly (l-lactide-co-glycolide) copolymers and medical devices containing same|
|WO2007089347A1 *||Dec 22, 2006||Aug 9, 2007||Advanced Cardiovascular System||Method of fabricating an implantable medical device using gel extrusion and charge induced orientation|
|WO2008011613A2 *||Jul 20, 2007||Jan 24, 2008||Robert J Cottone||Bioabsorbable polymeric medical device|
|WO2008036490A1 *||Aug 23, 2007||Mar 27, 2008||Boston Scient Scimed Inc||Ureteral stent having variable hardness|
|WO2009055426A2 *||Oct 22, 2008||Apr 30, 2009||Abbott Cardiovascular Systems||Random amorphous terpolymer containing lactide and glycolide|
|WO2010046637A2||Oct 21, 2009||Apr 29, 2010||Smith & Nephew Plc||Coating ii|
|WO2010132257A2 *||May 5, 2010||Nov 18, 2010||Abbott Cardiovascular Systems Inc.||Polymers comprising amorphous terpolymers and semicrystalline blocks|
|WO2010141173A1 *||May 4, 2010||Dec 9, 2010||Abbott Cardiovascular Systems Inc.||Terpolymers containing lactide and glycolide|
| || |
|U.S. Classification||604/8, 604/540, 128/898, 606/154|
|International Classification||A61L31/00, A61F2/94, A61L31/14, A61F2/02, A61F2/00, A61L31/06, A61B19/00|
|Cooperative Classification||A61F2002/048, A61B19/54, A61F2210/0004, A61L31/06, A61F2250/0098, A61F2/94, A61L31/148|
|European Classification||A61L31/06, A61L31/14K, A61F2/94|
|Aug 18, 2005||AS||Assignment|
Owner name: THE GOVERNOR AND COMPANY OF THE BANK OF SCOTLAND,
Free format text: SECURITY AGREEMENT;ASSIGNOR:CABOT TECHNOLOGY CORPORATION;REEL/FRAME:016418/0199
Effective date: 20050804
|Jul 27, 2005||AS||Assignment|
Owner name: CABOT TECHNOLOGY CORPORATION, PENNSYLVANIA
Free format text: RELASE OF SECURITY AGREEMENT;ASSIGNOR:ANTARES CAPITAL CORPORATION;REEL/FRAME:016309/0441
Effective date: 20050721
|Dec 29, 2003||AS||Assignment|
Owner name: ANTARES CAPITAL CORPORATION, AS AGENT, ILLINOIS
Free format text: SECURITY INTEREST;ASSIGNOR:CABOT TECHNOLOGY CORPORATION;REEL/FRAME:014836/0157
Effective date: 20031219
Owner name: CABOT TECHNOLOGY CORPORATION, MASSACHUSETTS
Free format text: RELEASE AND REASSIGNMENT;ASSIGNOR:JPMORGAN CHASE BANK, AS COLLATERAL AGENT (F/K/A THE CHASE MANHATTAN BANK);REEL/FRAME:014836/0610
Owner name: ANTARES CAPITAL CORPORATION, AS AGENT 311 S. WACKE
Owner name: CABOT TECHNOLOGY CORPORATION 136 TURNPIKE ROADSOUT
|Jul 15, 2003||FPAY||Fee payment|
Year of fee payment: 12
|Oct 4, 2000||AS||Assignment|
Owner name: CHASE MANHATTAN BANK, THE, NEW YORK
Free format text: SECURITY AGREEMENT;ASSIGNOR:CABOT TECHNOLOGY CORPORATION;REEL/FRAME:011170/0470
Effective date: 19991112
Owner name: CHASE MANHATTAN BANK, THE 270 PARK AVENUE NEW YORK
|Jul 26, 1999||FPAY||Fee payment|
Year of fee payment: 8
|Jul 16, 1999||AS||Assignment|
Owner name: CABOT TECHNOLOGY CORPORATION, A CORP. OF DELAWARE,
Free format text: RELEASE OF COLLATERAL ASSIGNMENT OF PATENTS (ISSUED);ASSIGNOR:FIRST INTERSTATE BANK OF CALIFORNIA;REEL/FRAME:010095/0210
Effective date: 19990119
|Jan 30, 1996||AS||Assignment|
Owner name: FIRST INTERSTATE BANK OF CALIFORNIA, CALIFORNIA
Free format text: COLLATERAL ASSIGNMENT;ASSIGNOR:CABOT TECHNOLOGY CORPORATION;REEL/FRAME:007644/0552
Effective date: 19951122
|Jul 31, 1995||FPAY||Fee payment|
Year of fee payment: 4
|Jul 6, 1993||CC||Certificate of correction|
|Feb 25, 1993||AS||Assignment|
Owner name: CABOT TECHNOLOGY CORPORATION, DELAWARE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:MEDICAL ENGINEERING CORPORATION;REEL/FRAME:006431/0978
Effective date: 19920729
|Jul 30, 1990||AS||Assignment|
Owner name: MEDICAL ENGINEERING CORPORATION, 3037 MT. PLEASANT
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SINCLAIR, RICHARD G.;GOLDBERG, JAY;REEL/FRAME:005395/0256;SIGNING DATES FROM 19900625 TO 19900702